Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION.

The European Union’s drug regulator said it would review two studies that link Novo Nordisk’s blockbuster diabetes drug Ozempic to a rare eye condition.

The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease. The studies published earlier this week had found Ozempic significantly increases the risk of type 2 diabetes patients developing NAION (non-arteritic anterior ischemic optic neuropathy),

Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.

Danish studies have found a potential link between the diabetes drug Ozempic and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). The Danish Medicines Agency has requested the European Pharmacovigilance Risk Assessment Committee to evaluate these findings,

New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines Agency calls for European review.

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare sight-threatening eye condition.

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.

Denmark's drug regulator has asked the European Medicine Agency's safety committee to evaluate two studies that found a potential link between Novo Nordisk's (NVO) type 2 diabetes drug Ozempic (semaglutide) and a rare eye condition.